Spectral AI's DeepView AI & Predictive Diagnostics Spectral AI (NASDAQ: MDAI), an AI company based in Dallas, is making a significant impact in the field of wound care with its innovative DeepView AI® technology. The company's focus is on developing predictive diagnostics that enable faster and more accurate treatment decisions, initially targeting patients with burns and diabetic foot ulcers.
DeepView AI is a cutting-edge diagnostic device that provides clinicians with objective and immediate assessments of a wound's healing potential before any medical intervention or treatment. By harnessing the power of AI algorithms, Spectral AI aims to surpass the current standard of care in wound management, ultimately improving patient outcomes and reducing healthcare costs.
The pivotal study recently initiated by Spectral AI aims to validate the effectiveness of DeepView AI® in assessing burn wounds. The study will be conducted in various clinical sites across the United States and will enroll both adult and pediatric patients. The company expects the study to demonstrate the superior accuracy and speed of DeepView AI® in predicting burn wound healing potential, surpassing the methods currently in use.
Spectral AI has been working diligently to secure non-dilutive government funding to support its research and development efforts. Since 2019, the company has utilized $251 million in government funding to validate DeepView for burn indications while also pursuing other clinical indications, such as diabetic foot ulcers. By adopting a "one platform—multiple clinical indications" strategy, Spectral AI aims to make a significant impact in various areas of medical diagnostics.